Define Ventures Appoints Carolyn Magill, Boosting Support for Hims & Hers Health
- Carolyn Magill joins Define Ventures, enhancing support for innovative health tech companies like Hims & Hers Health.
- Her expertise in health data applications aligns with Define Ventures’ mission to foster impactful collaborations in health technology.
- Define Ventures aims to nurture emerging health tech leaders, including Hims & Hers, through strategic partnerships and investments.
Define Ventures Enhances Leadership with Appointment of Carolyn Magill
In a significant development within the health tech investment landscape, Define Ventures has appointed Carolyn Magill as a venture partner. Magill, who previously served as CEO of Aetion, brings with her 25 years of extensive experience in the healthcare sector, which includes notable roles that have shaped her expertise in health data applications and regulatory compliance. Her leadership at Aetion involved transforming real-world data into regulatory-grade evidence, a skill that aligns well with Define Ventures’ focus on scaling innovative health tech companies across payer, provider, and pharmaceutical sectors.
Magill's strategic insight is expected to enhance Define Ventures’ mission of fostering impactful collaborations in health technology. As a venture partner, she will collaborate closely with the firm’s founders and a robust team of industry veterans, including Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder and former CEO of Evolent Health. This leadership trio aims to support early-stage companies by leveraging their vast networks and operational expertise. Magill’s appointment is particularly timely as Define Ventures manages $800 million in assets and is actively seeking to partner with emerging health tech entrepreneurs, including notable companies like Hims & Hers Health.
Lynne Chou O'Keefe, founder and managing partner at Define Ventures, commends Magill’s extensive background in data and artificial intelligence applications, especially within the pharmaceutical landscape. This expertise is anticipated to significantly influence the trajectory of health tech innovations, further solidifying Define Ventures’ position in a rapidly evolving market. Magill herself has expressed enthusiasm about joining the firm, highlighting the strength of its founder community and the collaborative environment that Define Ventures fosters, which is critical for the growth of startups in the healthcare domain.
In addition to the appointment of Carolyn Magill, Define Ventures continues to expand its influence in the health tech sector by forming strategic partnerships with over two dozen entrepreneurs. This collaborative approach not only enhances the potential for innovation but also aligns with the increasing demand for data-driven solutions in healthcare. The firm’s investment strategy focuses on companies at seed, series A, and series B stages, further demonstrating its commitment to nurturing the next generation of health tech leaders.
As the health tech ecosystem evolves, Define Ventures’ strengthened leadership under Carolyn Magill promises to drive significant advancements in healthcare innovation, particularly in the application of real-world data and artificial intelligence, vital for the future of the industry. This strategic enhancement positions both the firm and its portfolio companies, such as Hims & Hers, for greater success in an increasingly competitive landscape.